FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data

Replimune shares plummeted 40% on concerns FDA scientists are still skeptical of its melanoma drug. Elsewhere, investors had a muted reaction to a first-of-its-kind study result.